AMBS:OTC-Amarantus BioScience Holdings Inc (USD)

COMMON STOCK | Biotechnology | OTC

Last Closing Price

USD 0.01

Change

+0.00 (+12.50)%

Market Cap

USD 3.22M

Volume

0.87M

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict


Amarantus BioScience Holdings Inc (AMBS) Stock Analysis:
Based on the Amarantus BioScience Holdings Inc stock forecasts from 0 analysts, the average analyst target price for Amarantus BioScience Holdings Inc is not available over the next 12 months. Amarantus BioScience Holdings Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Amarantus BioScience Holdings Inc is Bearish, which is based on 1 positive signals and 5 negative signals. At the last closing, Amarantus BioScience Holdings Inc’s stock price was USD 0.01. Amarantus BioScience Holdings Inc’s stock price has changed by +0.00 % over the past week, +0.00 % over the past month and +16.13 % over the last year.

About

Amarantus BioScience Holdings, Inc., a biopharmaceutical company, focuses on the development of diagnostic and therapeutic product candidates in the areas of neurology, psychiatry, ophthalmology, and regenerative medicine. The company's diagnostic products in development include ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-12-07 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NONOF Novo Nordisk A/S

+5.09 (+4.81%)

USD244.19B 34.81 3.81
CSLLY CSL Limited

+2.67 (+2.54%)

USD96.13B 40.36 28.63
CMXHF CSL Limited

N/A

USD96.13B 39.96 27.59
WXXWY WuXi Biologics (Cayman) Inc

-0.10 (-0.42%)

USD57.70B 128.89 16.74
WXIBF WuXi Biologics

-0.11 (-0.84%)

USD57.70B 125.84 16.74
GNMSF Genmab A/S

+32.64 (+9.06%)

USD24.43B 54.48 6.05
UCBJY UCB SA

+0.32 (+0.58%)

USD20.50B 20.07 14.63
UCBJF UCB SA

-5.26 (-4.54%)

USD20.50B 21.10 14.63
SBHMY Sino Biopharmaceutical Limited

N/A

USD13.74B 8.48 1.04
SBMFF Sino Biopharmaceutical Limited

-0.04 (-4.97%)

USD13.74B 8.73 1.04

ETFs Containing AMBS

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -10.00% 58% F 38% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -10.00% 58% F 37% F
Trailing 12 Months  
Capital Gain 16.13% 66% D 56% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 16.13% 65% D 54% F
Trailing 5 Years  
Capital Gain -72.83% 42% F 18% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -72.83% 42% F 18% F
Average Annual (5 Year Horizon)  
Capital Gain -11.90% 20% F 9% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -11.90% 20% F 8% F
Risk Return Profile  
Volatility (Standard Deviation) 77.92% 51% F 38% F
Risk Adjusted Return -15.27% 21% F 16% F
Market Capitalization 3.22M 30% F 24% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 1.10 84% B 92% A-
Price/Book Ratio 53.19 10% F 4% F
Price / Cash Flow Ratio -1.80 44% F 68% D+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital 10.46% 62% D- 73% C
Return on Assets N/A N/A N/A N/A N/A
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.38 69% D+ 72% C-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.